Zhongzhu Medical Holdings Co Ltd (SHG:600568) — Market Cap & Net Worth
Market Cap & Net Worth: Zhongzhu Medical Holdings Co Ltd (600568)
Zhongzhu Medical Holdings Co Ltd (SHG:600568) has a market capitalization of $691.14 Million (CN¥4.72 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #10784 globally and #3005 in its home market, demonstrating a -8.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhongzhu Medical Holdings Co Ltd's stock price CN¥2.37 by its total outstanding shares 1992869681 (1.99 Billion). Review 600568 current and long-term liabilities to assess the company's total debt and financial obligations.
Zhongzhu Medical Holdings Co Ltd Market Cap History: 2015 to 2026
Zhongzhu Medical Holdings Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.45 Billion to $691.14 Million (-9.14% CAGR).
Zhongzhu Medical Holdings Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhongzhu Medical Holdings Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.27x
Zhongzhu Medical Holdings Co Ltd's market cap is 1.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.57 Billion | $1.10 Billion | $294.17 Million | 2.34x | 8.72x |
| 2017 | $2.25 Billion | $981.02 Million | $169.34 Million | 2.29x | 13.29x |
| 2018 | $664.89 Million | $572.86 Million | -$1.89 Billion | 1.16x | N/A |
| 2019 | $510.33 Million | $696.17 Million | -$369.50 Million | 0.73x | N/A |
| 2020 | $405.35 Million | $727.47 Million | $3.22 Million | 0.56x | 125.93x |
| 2021 | $571.57 Million | $581.06 Million | -$211.28 Million | 0.98x | N/A |
| 2022 | $548.24 Million | $505.97 Million | -$799.26 Million | 1.08x | N/A |
| 2023 | $501.59 Million | $638.56 Million | -$343.94 Million | 0.79x | N/A |
| 2024 | $379.11 Million | $521.39 Million | -$620.22 Million | 0.73x | N/A |
| 2025 | $731.96 Million | $577.34 Million | -$114.19 Million | 1.27x | N/A |
Competitor Companies of 600568 by Market Capitalization
Companies near Zhongzhu Medical Holdings Co Ltd in the global market cap rankings as of June 23, 2026.
Key companies related to Zhongzhu Medical Holdings Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Zhongzhu Medical Holdings Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhongzhu Medical Holdings Co Ltd's market cap moved from $2.45 Billion to $ 691.14 Million, with a yearly change of -9.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥691.14 Million | -5.58% |
| 2025 | CN¥731.96 Million | +93.08% |
| 2024 | CN¥379.11 Million | -24.42% |
| 2023 | CN¥501.59 Million | -8.51% |
| 2022 | CN¥548.24 Million | -4.08% |
| 2021 | CN¥571.57 Million | +41.01% |
| 2020 | CN¥405.35 Million | -20.57% |
| 2019 | CN¥510.33 Million | -23.25% |
| 2018 | CN¥664.89 Million | -70.45% |
| 2017 | CN¥2.25 Billion | -12.32% |
| 2016 | CN¥2.57 Billion | +4.55% |
| 2015 | CN¥2.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Zhongzhu Medical Holdings Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $691.14 Million USD |
| MoneyControl | $691.14 Million USD |
| MarketWatch | $691.14 Million USD |
| marketcap.company | $691.14 Million USD |
| Reuters | $691.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhongzhu Medical Holdings Co Ltd
Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China. The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment. It is also involved in produc… Read more